ArticleJTCVS open2026
The surgical management of mediastinal paragangliomas: A modern series reflecting true collaboration between cardiac and thoracic surgeons.
Article in JTCVS open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The study objective was to evaluate the perioperative management and outcomes of operation for patients undergoing mediastinal paraganglioma resection at Keck Medical Center of University of Southern California. Methods: Six patients underwent surgical management for mediastinal paraganglioma from 2018 to 2024. Perioperative data were collected through retrospective review of the electronic medical record. Results: The median age was 61 years (range, 27-69). Five patients (83%) demonstrated elevated levels of urinary or plasma metanephrines. Germline genetic testing demonstrated a pathogenic mutation consistent with paraganglioma-pheochromocytoma syndrome in 3 patients (50%). A multidisciplinary approach was used in all cases, with cardiac and thoracic surgical staff attending to each patient. Operative approach was via median sternotomy in 4 patients (67%), clamshell thoracotomy in 1 patient (17%), and right posterolateral thoracotomy in 1 patient (17%). Cardiopulmonary bypass was used in 3 patients (50%); 2 patients required great vessel transection for exposure, and 1 patient required en bloc resection of the right main coronary due to tumor encasement. R0 resection was achieved in all patients. Median intensive care unit and hospital length of stay were 2.5 days (range, 1-4) and 5 days (range, 4-9), respectively. The predominant method of postoperative surveillance was biannual chest computed tomography, with no patients demonstrating radiographic evidence of recurrence during a median follow-up of 22.5 months (range, 6.5-85). Conclusions: Surgical resection of mediastinal paraganglioma is safe and feasible with a multidisciplinary approach. The use of cardiopulmonary bypass, although occasionally necessary, did not result in adverse outcomes. All patients achieved an R0 resection with minimal postoperative complications, and no evidence of recurrence has been observed during the follow-up period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.